(Q40167162)

English

Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells

scientific article published on February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Osamu Shimada

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Xiuxian Wu

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Xinghua Jin

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Mohammed Ahmed Abdel-Muneem Nouh

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Michele Fiscella

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Vivian Albert

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Tadashi Matsuda

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Yoshiyuki Kakehi

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

1 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

395-401

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

TRAIL: a molecule with multiple receptors and control mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Apoptosis control by death and decoy receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

A matter of life and death

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Apoptosis-targeted therapies for cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.007

7 January 2021

Identifiers

10.1016/J.UROLOGY.2006.12.007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40167162&oldid=1887853373"